(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Celcuity's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast CELC's revenue for 2026 to be $1,931,871,335, with the lowest CELC revenue forecast at $789,017,508, and the highest CELC revenue forecast at $3,414,772,643. On average, 10 Wall Street analysts forecast CELC's revenue for 2027 to be $15,446,734,392, with the lowest CELC revenue forecast at $7,255,333,411, and the highest CELC revenue forecast at $30,423,815,505.
In 2028, CELC is forecast to generate $33,250,526,717 in revenue, with the lowest revenue forecast at $17,458,146,021 and the highest revenue forecast at $51,176,012,454.